108047-39-8Relevant articles and documents
New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives
Baska, Ferenc,Bata, Imre,Bozó, éva,Cselenyák, Attila,Domány-Kovács, Katalin,Kordás, Krisztina Szondiné,Kurkó, Dalma,Makó, Attila,Mohácsi, Réka,Szántó, Gábor
, (2020)
Solid preclinical evidence links vasopressin to social behavior in animals, so, extensive work has been initiated to find new vasopressin V1a receptor antagonists which can improve deteriorated social behavior in humans and can treat the core symptoms of
"Methylene Bridge" to 5-HT3 Receptor Antagonists: Conformationally Constrained Phenylguanidines
Abdelkhalek, Ahmed S.,Alley, Genevieve S.,Alwassil, Osama I.,Khatri, Shailesh,Mosier, Philip D.,Nyce, Heather L.,White, Michael M.,Schulte, Marvin K.,Dukat, Ma?gorzata
, p. 1380 - 1389 (2018/11/23)
Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazo
Preparation of triazolobenzodiazepine derivatives as Vasopressin V1a antagonists
Beal, David M.,Bryans, Justin S.,Johnson, Patrick S.,Newman, Julie,Pasquinet, Christelle,Peakman, Torren M.,Ryckmans, Thomas,Underwood, Toby J.,Wheeler, Simon
body text, p. 5913 - 5917 (2011/11/14)
This Letter describes the synthesis of a number of fused tricyclic and bicyclic triazolobenzodiazepines for the Vasopressin V1a antagonist programme.